RT Journal Article
T1 Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy.
A1 Olivares-Hernandez, Alejandro
A1 Del-Barco-Morillo, Edel
A1 Miramontes-Gonzalez, Jose Pablo
A1 Figuero-Perez, Luis
A1 Perez-Belmonte, Luis
A1 Martin-Vallejo, Javier
A1 Martin-Gomez, Teresa
A1 Escala-Cornejo, Roberto
A1 Vidal-Tocino, Rosario
A1 Bellido-Hernandez, Lorena
A1 Gonzalez-Sarmiento, Rogelio
A1 Ludeña-de-la-Cruz, Maria Dolores
A1 Cruz-Hernandez, Juan Jesus
A1 Parra-Perez, Carmen
K1 Biomarkers
K1 Immune checkpoint inhibitors
K1 Immunotherapy
K1 Non-small cell lung cancer
K1 p53 protein
AB Determining predictive biomarkers for immune checkpoint inhibitors (ICIs) is a current challenge in oncology. Previous studies on non-small cell lung cancer (NSCLC) have shown how TP53 gene mutations are correlated with different responses to ICIs. Strong and diffuse immuno-expression of p53 by immunohistochemistry (IHC) is interpreted as a likely indicator of a TP53 gene mutation. We aimed to assess the p53 protein expression via IHC in NSCLC as a predictive biomarker of the response to ICIs. This was a retrospective hospital-based study of patients with NSCLC treated with Nivolumab in the University Hospital of Salamanca. All diagnostic biopsies were studied via IHC (measuring p53 protein expression, peroxidase anti-peroxidase immunohistochemistry technique using Leica BOND Polymer development kits). Survival analysis was performed by subgroups of expression of p53 and other factors using the Kaplan-Meier estimator and Cox proportional-hazards model. Seventy-three patients were included (59 men and 14 women). The median age was 68 (44-84) years. Thirty-six biopsies were adenocarcinoma, 34 were squamous, and three were undifferentiated. In 41 biopsies (56.2%), the cellular expression of p53 was  A trend toward a greater response to ICIs was observed in the PFS and OS of patients with high expression of p53 by IHC (TP53 mutation), especially in the PD-L1 negative adenocarcinoma subgroup. These results will make it possible to make future modifications to the clinical guidelines of NSCLC according to the expression of p53.
PB IMR Press
YR 2022
FD 2022-03-08
LK http://hdl.handle.net/10668/21810
UL http://hdl.handle.net/10668/21810
LA en
NO Olivares-Hernández A, Del Barco Morillo E, Miramontes-González JP, Figuero-Pérez L, Pérez-Belmonte L, Martín-Vallejo J, et al. Immunohistochemical Assessment of the P53 Protein as a Predictor of Non-Small Cell Lung Cancer Response to Immunotherapy. Front Biosci (Landmark Ed). 2022 Mar 8;27(3):88
DS RISalud
RD Apr 10, 2025